Open an account

Interpace Biosciences

IDXG · OTC

$5.30+$0.30 (+6.00%)TodayMarket closed ·
Prev close $5.00

About IDXG

Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. The company is headquartered in Parsippany, New Jersey and currently employs 102 full-time employees. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The firm develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. The company has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.

Employees
102
Headquarters
Parsippany, New Jersey
Listed
May 19, 1998
Sector
Health Care
Industry
Health Care Providers & Services
Website
interpace.com

IDXG key statistics

Market cap
31.28M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
7.71K
Volume
1.25K
Open price
$5.10
High today
$5.30
Low today
$5.10
52 Week high
$2.40
52 Week low
$0.77

Interpace Biosciences (IDXG) at a glance

As of Oct 20, 2026, Interpace Biosciences (IDXG) shares are priced at $5.30, giving the company a market cap of 31.28M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.10 and $5.30. The current price is 3.9% above the day's low and 0.0% below its high.

Volume so far is 1.25K shares, below the average of 7.71K shares a day.

Over the past year Interpace Biosciences has ranged from $0.77 to $2.40, and now sits 278% of the way up that range.

Interpace Biosciences met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY23 it reported $0.09 per share against an estimate of $0.00.

IDXG earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 18.3% on average.

  1. Q1 FY21: reported -$5.15 per share against an estimate of -$7.29
  2. Q2 FY21: reported -$4.50 per share against an estimate of -$5.15
  3. Q3 FY21: reported -$4.25 per share against an estimate of -$3.16
  4. Q4 FY21: reported -$4.50 per share against an estimate of -$1.63
  5. Q1 FY22: reported -$2.80 per share against an estimate of -$4.08
  6. Q2 FY22: reported -$4.65 per share against an estimate of -$2.65
  7. Q3 FY22: reported -$16.75 per share against an estimate of -$1.27
  8. Q2 FY23: reported $0.09 per share against an estimate of $0.00

Similar companies

Companies in the same industry as Interpace Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.